As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of MapLight Therapeutics, Inc. The largest reported stake is Catalyst4, Inc.'s, at 49.9%. 9 filings are on record since November 4, 2025 (Schedule 13D/A, August 18, 2026).
Sell to companies like MapLight Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Nan Fung Group Holdings Limited · Sole voting: 0 · Shared voting: 2,915,874 · Sole dispositive: 0 · Shared dispositive: 2,915,874 · SCHEDULE 13G, 2026-08-20
- · Reporting person: Catalyst4, Inc. · Sole voting: 27,536,011 · Shared voting: 0 · Sole dispositive: 27,536,011 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-08-18
- · Holder: Catalyst4, Inc. · Percent: 47.9% · SCHEDULE 13D/A
- · Reporting person: Novo Holdings A/S · Sole voting: 2,086,622 · Shared voting: 0 · Sole dispositive: 2,086,622 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-07-31
- · Holder: T. Rowe Price Investment Management, Inc. · Percent: 7.4% · SCHEDULE 13G/A
MapLight Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-11-04. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Catalyst4, Inc. | 49.9% | 27,536,011 | SCHEDULE 13D/A, 2026-08-18 | 2026-08-14 |
| T. Rowe Price Investment Management, Inc. | 7.4% | 3,137,558 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 7.1% | 3,226,400 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 |
| Nan Fung Group Holdings Limited | 5.5% | 2,915,874 | SCHEDULE 13G, 2026-08-20 | 2026-08-13 |
| Novo Holdings A/S | 4.9% | 2,086,622 | SCHEDULE 13D/A, 2026-07-31 | 2026-07-30 |
Holding shares or following this stake? See who's behind MapLight Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on MapLight Therapeutics, Inc. and the records around it.
MapLight Therapeutics, Inc. elsewhere on the record
- Leadership changes Jun 2026
- Form D filing Jul 2025
- Who owns it
Companies that share a holder
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch MapLight Therapeutics, Inc.
Get an email when MapLight Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on MapLight Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on MapLight Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MapLight Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Catalyst4, Inc. | 27,536,011 | 0 | 27,536,011 | 0 | SCHEDULE 13D/A, 2026-08-18 |
| Robert Brown | 0 | 27,536,011 | 0 | 27,536,011 | SCHEDULE 13D/A, 2026-08-18 |
| Ekemini Riley | 0 | 27,536,011 | 0 | 27,536,011 | SCHEDULE 13D/A, 2026-08-18 |
| Mark Vorsatz | 0 | 27,536,011 | 0 | 27,536,011 | SCHEDULE 13D/A, 2026-08-18 |
| Nan Fung Group Holdings Limited | 0 | 2,915,874 | 0 | 2,915,874 | SCHEDULE 13G, 2026-08-20 |
| NF Investment Holdings Limited | 0 | 2,911,774 | 0 | 2,911,774 | SCHEDULE 13G, 2026-08-20 |
| Nan Fung Life Sciences Holdings Limited | 0 | 1,283,052 | 0 | 1,283,052 | SCHEDULE 13G, 2026-08-20 |
| NFLS Platform Holdings Limited | 0 | 671,606 | 0 | 671,606 | SCHEDULE 13G, 2026-08-20 |
| Pivotal Life Sciences Holdings Limited | 0 | 611,446 | 0 | 611,446 | SCHEDULE 13G, 2026-08-20 |
| Pivotal Partners Ltd | 0 | 611,446 | 0 | 611,446 | SCHEDULE 13G, 2026-08-20 |
| Pivotal bioVenture Partners Fund II G.P. Ltd | 0 | 611,446 | 0 | 611,446 | SCHEDULE 13G, 2026-08-20 |
| Pivotal bioVenture Partners Fund II, L.P. | 0 | 611,446 | 0 | 611,446 | SCHEDULE 13G, 2026-08-20 |
| NFLS Beta Limited | 0 | 671,606 | 0 | 671,606 | SCHEDULE 13G, 2026-08-20 |
| Permwell Management Limited | 0 | 1,628,722 | 0 | 1,628,722 | SCHEDULE 13G, 2026-08-20 |
| Novo Holdings A/S | 2,086,622 | 0 | 2,086,622 | 0 | SCHEDULE 13D/A, 2026-07-31 |
The latest filing identifies MapLight Therapeutics, Inc. by CUSIP 56565P103 and gives its principal executive office as 800 Chesapeake Drive, Redwood City, CA 94063 (SCHEDULE 13G, 2026-08-20).
What the percentages are based on
The information required by this item with respect to each Reporting Person is set forth in Row 11 of the cover pages to this Schedule 13G.Nan Fung Group Holdings Limited, SCHEDULE 13G, 2026-08-20
Source of funds (Item 3)
Item 3 of the Original Schedule 13D is amended as follows: The aggregate purchase price for the shares acquired in the PIPE Offering (as defined below) by the Reporting Persons was $83,400,153.82. The source of these funds was the working capital of Catalyst4.Catalyst4, Inc., SCHEDULE 13D/A, 2026-08-18
Purpose of Transaction (Item 4)
Catalyst4, Inc.
Item 4 of the Original Schedule 13D is hereby amended as follows: On August 13, 2026, Catalyst entered into a securities purchase agreement, which is filed as Exhibit 99.4 to this Statement ("Securities Purchase Agreement") with the Issuer, pursuant to which the Catalyst agreed to purchase an aggregate of (i) 4,400,000 shares of the Issuer's voting common stock and (ii) accompanying pre-funded warrants to purchase up to 2,928,686 shares of voting common stock (the "Pre-Funded Warrants"), which is filed as Exhibit 99.5 to this Statement (the "PIPE Offering"). The purchase price per share of voting common stock is $11.38 per share (the "Purchase Price") and the purchase price for the Pre-Funded Warrants is the Purchase Price minus $0.0001 per share underlying the Pre-Funded Warrants. The PIPE Offering closed on August 14, 2026. The Pre-Funded Warrants are exercisable at any time and do not expire until exercised in full, however, the Pre-Funded Warrants may not be exercised if the aggregate number of shares of voting common stock beneficially owned by the Reporting Person immediately following such exercise would exceed 49.99%. Accordingly, only 2,229,322 of the Pre-Funded Warrants are included in the beneficial ownership reported by any of the Reporting Persons on their respective cover pages because they are exercisable within 60 days of August 14, 2026.Item 4 of the SCHEDULE 13D/A filed 2026-08-18
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-04 | Novo Holdings A/S | 8.4% | SCHEDULE 13D |
| 2025-11-20 | Catalyst4, Inc. | 45.1% | SCHEDULE 13D |
| 2026-02-17 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 7.1% | SCHEDULE 13G |
| 2026-02-17 | T. Rowe Price Investment Management, Inc. | 6.2% | SCHEDULE 13G |
| 2026-05-15 | T. Rowe Price Investment Management, Inc. | 7.4% | SCHEDULE 13G/A |
| 2026-07-31 | Novo Holdings A/S | 4.9% | SCHEDULE 13D/A |
| 2026-08-03 | Catalyst4, Inc. | 47.9% | SCHEDULE 13D/A |
| 2026-08-18 | Catalyst4, Inc. | 49.9% | SCHEDULE 13D/A |
| 2026-08-20 | Nan Fung Group Holdings Limited | 5.5% | SCHEDULE 13G |
Questions about who owns MapLight Therapeutics, Inc.
Who owns MapLight Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of MapLight Therapeutics, Inc.: Catalyst4, Inc. (49.9%, Schedule 13D/A, filed 2026-08-18), T. Rowe Price Investment Management, Inc. (7.4%, Schedule 13G/A, filed 2026-05-15), Forbion Growth Opportunities Fund III Cooperatief U.A. (7.1%, Schedule 13G, filed 2026-02-17) and Nan Fung Group Holdings Limited (5.5%, Schedule 13G, filed 2026-08-20).
Who are the largest shareholders of MapLight Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of MapLight Therapeutics, Inc. on this page are Catalyst4, Inc. (49.9%), T. Rowe Price Investment Management, Inc. (7.4%) and Forbion Growth Opportunities Fund III Cooperatief U.A. (7.1%).
When did Catalyst4, Inc. buy into MapLight Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Catalyst4, Inc. on this page is the Schedule 13D, filed 2025-11-20, reporting 45.1%; its latest, Schedule 13D/A filed 2026-08-18, reports 49.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for MapLight Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 18, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| September 9, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| June 18, 2026 | Leadership change: Jonathan Gillis appointed, Chief Financial Officer | — | Leadership changes | Source |
| April 29, 2026 | Leadership change: Robert Malenka departs | — | Leadership changes | Source |
| October 6, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| September 19, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| July 28, 2025 | Form D, private offering | $188.19M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for MapLight Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.